Abstract: A clear aqueous formulation for topical application in the oral cavity of humans to treat leukoplakia contains water, ?-carotene, a water miscible polyol, an unsaturated fatty acid ester, and a surfactant, preferably polyethoxylated castor oil or POE(20) sorbitan monooleate. The formulation preferably also contains a pharmaceutically acceptable anti-oxidant, preferably d-alpha-tocopherol (vitamin E), and is in the form of an oral rinse or as a gel well suited for spreading on gums or other parts of the oral cavity. The formulation is applied in a gel form on a substantially regular daily basis to areas in the oral cavity where leukoplakia lesions are present. Persistent application of the gel results in substantial diminution or total elimination of the leukoplakia lesions.

Abstract: A method of treating addiction to a chemical, and products containing the chemical, is provided, which comprises administering to a human in need thereof, an effective amount of a pharmaceutical composition which comprises a sex steroid precursor. The chemical is one or more chemicals selected from the group consisting of nicotine, caffeine, alcohol, methadone, heroin, cocaine and subutex. The sex steroid precursor is selected from the group which comprises DHEA, DHEAS, analogues of DHEA, and analogues of DHEAS. A method of preparing a medicinally effective treatment for addiction to a chemical or to products containing the chemical is also disclosed, which includes synthetically producing or extracting a sex steroid precursor from a source where said sex steroid precursor was naturally produced in vivo, and combining an amount of the sex steroid precursor sufficient to effectively treat a human addiction to the chemical with a pharmaceutically acceptable carrier, excipient or agent.

Abstract: Fluoroalkyl hydrocarbons as vehicles for pharmaceutical drugs are disclosed. These vehicles are particularly well-suited for delivering drugs which are insoluble in water or chemically unstable in aqueous media. Pharmaceutical solution compositions based on these vehicles have long shelf lives and provide improved drug bioavailability. In addition, the pharmaceutical compositions of the present invention are nonaqueous, and therefore do not require preservatives or tonicity agents. The invention is particularly useful in the field of ophthalmology.

Abstract: Methods of treating Parkinson's disease in a human by administering an effective amount of at least one monoamine oxidase (MAO) A inhibitor by a nasal, intrapulmonary or parenteral routes are disclosed. Reversible or irreversible MAO A inhibitors, or non-selective MAO inhibitors, can be used, and more than one MAO A inhibitor can be administered concurrently. The MAO A inhibitor can be administered in conjunction with other drugs, such as MAO B inhibitors.

Abstract: A method for rehydrating dry skin of an individual is disclosed. In accordance with the method, a balm of lanolin and hydroxyquinoline sulfate is first applied to the skin surface to be treated, wherein the skin surface is a hand or a foot of an individual. The skin surface is then covered with a cotton cover, and the cover is maintained over the skin surface for a predetermined period of time. The cover is then removed to reveal the rehydrated skin surface. A kit for practicing the invention is also provided.

Abstract: Stable aqueous iodine/iodide/iodate germicidal compositions are provided which have relatively high quantities of free iodine therein and also substantially maintain the starting amounts of available and free iodine throughout a storage period of at least about three months. The compositions of the invention contain from about 0.01-1.4% by weight available iodine, from about 10-125 ppm free iodine, from about 0.005-0.5% by weight iodate ion, from about 0.1-15% by weight of iodine complexing agent, from about 0.004-0.5% by weight iodide ion, and have a pH of from about 2.0-4.5.

Abstract: Novel urea derivatives and pharmaceutical compositions thereof are provided which inhibit platelet aggregation.

Abstract: An imidazopyridine derivative is disclosed of the formula [I]: ##STR1## wherein R.sup.1 is lower alkyl, R.sup.2 is a group of the formula ##STR2## where Z is oxygen atom, R.sup.0 is lower alkyl, R.sup.3 is carboxyl or lower alkoxycarbonyl and Ring A is tetrazolyl-substituted or unsubstituted phenyl, and pharmaceutically acceptable salt thereof, that are useful in prophylaxis and treatment of hypertension.

Abstract: Tetrahydroisoquinoline derivatives useful as fungicides are disclosed of formula [I]: ##STR1## wherein R.sup.1 represents C.sub.1 -C.sub.5 linear or branched alkyl, C.sub.2 -C.sub.5 linear or branched alkenyl, C.sub.2 -C.sub.5 linear or branched alkynyl; R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6, the same or different, represent hydrogen, C.sub.1 -C.sub.10 linear or branched alkyl, C.sub.3 -C.sub.10 linear or branched alkenyl, C.sub.2 -C.sub.10 linear or branched alkynyl, C.sub.1 -C.sub.10 linear or branched alkoxy, C.sub.2 -C.sub.10 linear or branched alkenyloxy, C.sub.2 -C.sub.10 linear or branched alkynyloxy, benzyloxy, hydroxy, haloalkyl, amino, mono- or di-substituted amino substituted with C.sub.1 -C.sub.4 linear or branched alkyl, phenyl or halogen; R.sup.2 and R.sup.3 may be bonded through a group of the formula --O--CH.sub.2).sub.m O-- wherein m represents integer of 1 or 2 or --CH.dbd.CH).sub.2 to form a ring; and R.sup.4 and R.sup.5 may be bonded through a group of the formula --O--CH.sub.2).

Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which Q, X, Z, G.sup.1, G.sup.2, G.sup.3 and G.sup.4 have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure.

Abstract: The invention relates to therapeutically active azaheterocyclic compounds and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.